US OptionsDetailed Quotes
TSVT241220P7500
- 4.14
- 0.000.00%
15min DelayClose Nov 22 16:00 ET
0.00High0.00Low
4.14Open4.14Pre Close0 Volume1 Open Interest7.50Strike Price0.00Turnover265.51%IV6.93%PremiumDec 20, 2024Expiry Date3.89Intrinsic Value100Multiplier25DDays to Expiry0.25Extrinsic Value100Contract SizeAmericanOptions Type-0.7571Delta0.1256Gamma0.87Leverage Ratio-0.0150Theta-0.0036Rho-0.66Eff Leverage0.0030Vega
2seventy bio Stock Discussion
2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third Quarter Revenue Performance
2seventy bio and Bristol Myers Squibbhave decided to discontinue enrollment in the Phase 3 KarMMa-9 studyevaluating Abecma in newly diagnosed multiple myeloma patients. This decision is expected to result in over $80 million in cost savings for 2seventy bio and accelerate their path to breakeven in 2025.
The company reports positive momentum for Abecma, wi...
$Supernus Pharmaceuticals (SUPN.US)$ : CRL 4/8/24 🙁
⇒ SPN-830
⇒ OFF episodes in PD
⇒ NDA
⇒ PDUFA: 4/5/24
$Legend Biotech (LEGN.US)$ & $Johnson & Johnson (JNJ.US)$ : Approved 🎉
⇒ CARVYKTI (cilta-cel)
⇒ Multiple myeloma
⇒ sBLA
⇒ PDUFA: 4/5/24
$AstraZeneca (AZN.US)$ : Approved 🎉
⇒ Enhertu
⇒ HER2+ solid tumors
⇒ sBLA
⇒ PDUFA: Q2 2024
$2seventy bio (TSVT.US)$ & $Bristol-Myers Squibb (BMY.US)$ : Approved 🎉
⇒ Abecma
⇒ Multiple myeloma
⇒ sBLA
⇒ Delayed PDUFA
$Vanda Pharmaceuticals (VNDA.US)$...
WSJ· 2 mins ago
Bristol Myers Squibb and 2seventy bio have won U.S. Food and Drug Administration approval for the earlier use of their Abecma gene therapy in the treatment course for people with the blood cancer multiple myeloma.
The companies on Friday said the FDA approved Abecma for the treatment of adults with relapsed or refractory multiple myeloma after two or more prior lines of therapy, ...
- Company Now Exclusively Focused on Development and Commercialization of Abecma -
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 1, 2024-- 2seventy bio, Inc. (Nasdaq: TSVT), announced today the completion of the asset purchase agreement (“APA”) by Regeneron Pharmaceuticals, Inc. Under the terms of the APA, Regeneron has acquired all onc...
No comment yet